



Published in final edited form as:

Mol Neurobiol. 2022 May ; 59(5): 3233–3253. doi:10.1007/s12035-022-02747-0.

Neutral sphingomyelinase 2 mediates oxidative stress effects on astrocyte senescence and synaptic plasticity transcripts

Zhihui Zhu¹, Zainuddin Quadri^{1,2}, Simone M. Crivelli¹, Ahmed Elsherbini¹, Liping Zhang^{1,2}, Priyanka Tripathi^{1,2}, Haiyan Qin¹, Emily Roush¹, Stefka D. Spassieva¹, Mariana Nikolova-Karakashian¹, Timothy S. McClintock¹, Erhard Bieberich^{1,2}

¹Department of Physiology, College of Medicine, University of Kentucky, Lexington, KY

²Veterans Affairs Medical Center, Lexington, KY 40502, United States

Abstract

We have shown that deficiency of neutral sphingomyelinase 2 (nSMase2), an enzyme generating the sphingolipid ceramide, improves memory in adult mice. Here, we performed sphingolipid and RNA-seq analyses on the cortex from 10-month-old nSMase2-deficient (*fro/fro*) and heterozygous (*+/fro*) mice. *fro/fro* cortex showed reduced levels of ceramide, particularly in astrocytes. Differentially abundant transcripts included several functionally related groups, with decreases in mitochondrial oxidative phosphorylation and astrocyte activation transcripts, while axon guidance and synaptic transmission and plasticity transcripts were increased, indicating a role of nSMase2 in oxidative stress, astrocyte activation, and cognition. Experimentally induced oxidative stress decreased the level of glutathione (GSH), an endogenous inhibitor of nSMase2, and increased immunolabeling for ceramide in primary *+/fro* astrocytes, but not in *fro/fro* astrocytes. β -galactosidase activity was lower in 5-weeks-old *fro/fro* astrocytes, indicating delayed senescence due to nSMase2 deficiency. In *fro/fro* cortex, levels of the senescence markers C3b and p27, and the proinflammatory cytokines interleukin 1 β , interleukin 6, and tumor necrosis factor α were reduced, concurrent with 2-fold decreased phosphorylation of their downstream target, protein kinase Stat3. RNA and protein levels of the ionotropic glutamate receptor subunit

Correspondence to: Dr. Erhard Bieberich, Department of Physiology, School of Medicine, University of Kentucky 780 Rose St., Room MS519. Lexington, KY 40536, Phone: 859-323-8079. Erhard.bieberich@uky.edu. **Co-corresponding author:** Dr. Stefka D. Spassieva, Department of Physiology, School of Medicine, University of Kentucky 780 Rose St., Room MS517A. Lexington, KY 40536, Phone: 859-323-9443. Stefanka.spassieva@uky.edu.

Authors' contribution

ZZ, ZQ, SMC, AE, LZ, PT, HQ, and ER planned and performed experiments, analyzed data, and wrote the manuscript, SDS, MNK, and TSM planned experiments, analyzed data and wrote the manuscript. E.B. supervised study, planned and performed experiments, analyzed data, and wrote the manuscript.

Conflict of interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials

The RNA-seq data have been submitted to the Gene Expression Omnibus (GEO) database (accession number GSE179045). The datasets used and/or analyzed during the current study are available from the corresponding author (Erhard.bieberich@uky.edu) on reasonable request.

Ethics approval

Mice were handled according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All procedures involving mice were approved by the Institutional Animal Care and Use Committee of University of Kentucky. This study did not involve human subjects.

Competing interests

The authors declare that they have no competing interests.

2B (*Grin2b*/NR2B) were increased by 2-fold, which was previously shown to enhance cognition. This was consistent with 3-fold reduced levels of exosomes carrying miR-223-3p, a micro-RNA downregulating NR2B. In summary, our data show that nSMase2 deficiency prevents oxidative stress-induced elevation of ceramide and secretion of exosomes by astrocytes that suppress neuronal function, indicating a role of nSMase2 in the regulation of neuroinflammation and cognition.

Keywords

Ceramide; oxidative stress; extracellular vesicles; *Grin2b*

Introduction

The loss of cognition induced by the development of dementia represents one of the main pathological symptoms of human aging. Aging-related cognitive decline in humans can begin as early as middle age (45-65 years old) [1]. Cognitive decline related to the aging brain is associated with oxidative stress and neuroinflammation [2]. Astrocytes, the most versatile cells in the central nervous system, play an important role in brain aging. The oxidative stress-preventing function of astrocytes is mainly due to their ability to generate endogenous anti-oxidants and regulate neuroinflammation [3]. Most recently, it was shown that in reactive astrocytes, the level of the sphingolipid ceramide was increased [4]. Studies from our laboratory and others have shown that astrocytes increase the level of ceramide due to the activation of neutral sphingomyelinase 2 (nSMase2) by amyloid beta (A β) peptide and proinflammatory cytokines, the levels of both of which are increased during normal aging and in Alzheimer's disease (AD) [4-12]. We discovered that nSMase2 inhibition or deficiency ameliorated AD pathology in the 5XFAD mouse model, including cognitive improvement [11,13]. Surprisingly, cognition was also improved in nSMase2-deficient mice without AD [11]. These data suggested that downregulation of ceramide generation is beneficial for cognitive performance and prompted us to investigate the function of nSMase2 in oxidatively stressed astrocytes and to determine the effects on transcripts associated with cognition in middle-aged mouse brain, the earliest time point for age-related cognitive decline in humans.

Activation of nSMase2 and in turn, ceramide generation is induced by oxidative stress [10]. Oxidative stress is downregulated by astrocytes that are the main source for glutathione (GSH), an endogenous antioxidant, the level of which is strongly correlated with cognitive performance in the aging brain [2]. The level of GSH determines the activation state of nSMase2 in hepatocytes [14,15]. Whether GSH also regulates nSMase2 in astrocytes is not known. If the GSH level drops below 5-8 mM, a concentration found in hepatocytes and astrocytes, nSMase2 is no longer inhibited and generates ceramide [3,16]. In neurons, activation of nSMase2 by reduction of GSH is not likely since the neuronal GSH concentration (< 1 mM) is far below the range required for nSMase2 inhibition [16]. Therefore, inhibition of nSMase2 by GSH is suggested to be critical for the regulation of ceramide levels in astrocytes, but not in neurons. As a consequence, ceramide levels

in nSMase2-deficient (*fro/fro*) astrocytes are expected to be insensitive to decreased GSH levels either as a result of aging or experimentally induced by oxidants.

In this study, we analyzed the ceramide and mRNA levels in the cortex of middle-aged (10-month-old) nSMase2-deficient (*fro/fro*) mice and control littermates (*+/fro* and/or wild type). In addition, we determined the effect of experimentally induced oxidative stress *in vitro* and analyzed proinflammatory cytokines and downstream cell signaling pathways activated by ceramide *in vivo*. Our studies show that nSMase2 deficiency decreased ceramide levels and neuroinflammation, while levels of transcripts encoding proteins important for neuronal development and function were increased. Further, we show that nSMase2 deficiency reduces the level of exosomes transporting a micro-RNA that suppresses expression of several genes important for neuronal function. These data indicate a critical role of nSMase2 in the regulation of cognition, particularly at an age when cognitive decline begins.

Methods

Animals and reagents

The *fro/fro* mouse was the gift from Dr. Christophe Poirier (Indiana University, Indianapolis). This carries a deletion of the C-terminal 33 amino acids in the sphingomyelin phosphodiesterase-3 (*Smpd3*) gene that encodes neutral sphingomyelinase 2 (nSMase2) (NCBI gene ID: 58994; [17]). Mice were handled according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All procedures involving mice were approved by the Institutional Animal Care and Use Committee of University of Kentucky. Procedures focused on the use of male mice based on our previous studies showing that nSMase2 deficiency improves cognition in male 5XFAD mice [11]. The antibodies, chemicals and reagents used in this study have been summarized and are listed in tables 2 and 3.

Primary cell culture

Primary astrocytes from *fro/fro* and littermate controls (wild type or heterozygous *+/fro*) mice were prepared according to the protocol we have used previously [11,18]. Astrocytes were maintained in DMEM with 10% FBS and 1% penicillin/streptomycin at 37 °C in a humidified atmosphere containing 5% CO₂. For all treatment procedures, including incubation with reagents and isolation of extracellular vesicles, astrocytes were first maintained for 48 h in serum-and phenol-red free DMEM medium.

Immunoblotting

Mouse brain cortex was solubilized by sonification in SDS-sample buffer containing 10% 2-mercaptoethanol and heated for 10 min at 95 °C prior to SDS-PAGE and immunoblotting. In detail, proteins were resolved by SDS gel electrophoresis on polyacrylamide gels (Biorad, Hercules, California) and transferred to nitrocellulose membranes (Bio-Rad, Hercules, California). Non-specific binding sites were blocked with 5% fat-free dry milk (Bio-Rad Hercules, California) in PBS containing 0.1% Tween-20 (PBST) followed by overnight incubation with primary antibodies. The primary and secondary antibodies diluted with different concentrations in PBST are listed in the table 1 of antibodies and reagents. Signals

were detected using either pico or femto chemiluminescent (ECL) horseradish peroxidase (HRP) substrate (Thermo Fisher, Massachusetts, USA). Blot images were captured by Azure c600 system (Azure Biosystems, California, USA), and quantificated by image J soft ware (<https://imagej.nih.gov/ij/download>).

Immunocytochemistry and fluorescence microscopy

Astrocytes grown on cover slips were fixed with 4% p-formaldehyde/0.5% glutaraldehyde/PBS for 20 min, followed by permeabilization with 0.2% Triton X-100 in PBS for 5-10 min at room temperature. Nonspecific binding sites were blocked with 3% ovalbumin/PBS for 1 h at 37 °C. Cells were incubated with primary antibodies at 4 °C overnight. The next day, cells were washed with PBS, followed by incubation with secondary antibodies for 2 h at room temperature. After washing with PBS, cover slips were mounted using Fluoroshield supplemented with DAPI (Sigma-Aldrich) to visualize the nuclei. Fluorescence microscopy was performed with a Nikon Ti2 Eclipse microscope equipped with NIS Elements software. Images were processed using a 3D deconvolution program as provided by the Elements software.

Image analysis of colocalization studies

A set of images was de-identified (blinded identifiers) and numbers assigned using a random generator program (random.org) available online. Colocalization was analyzed using the Nikon Elements software. The degree of colocalization was assessed by calculation of the Pearson's correlation coefficient for two fluorescence channels in overlays as previously described [19,20].

Lipid analysis

For ceramide analysis, brain tissues were sent to the lipidomics core facility at the Medical University of South Carolina, Charlston, SC (Dr. Besim Ogretmen, director) (<https://hollingscancercenter.musc.edu/>). Quantitative analyses of sphingolipids were based on previously published methods [21,22]. The concentration of ceramide species was quantified in the sphingolipidomics (LC-MS/MS) analysis core. The lipid concentration was normalized to lipid phosphate.

RNA-seq

RNA was extracted from the brain cortex (2 males *+/fro* and 2 males *fro/fro*; 10-month old) using the miniRNeasy extraction kit (Qiagen). The total RNA was submitted to Novogene (<https://en.novogene.com>) for quality control and RNA-seq analysis. Only the RNA with integrity numbers ≥ 8 , and of sufficient purity ($OD_{260/280}=1.8-2.2$; $OD_{260/230} \geq 1.8$) was used. The RNA-seq data were submitted to the Gene Expression Omnibus (GEO) database (accession number GSE179045).

Library preparation for transcriptome sequencing

A total amount of 0.4 μ g of RNA was used for cDNA library construction at Novogene using a NEBNext® Ultra 2 RNA Library Prep Kit for Illumina® (cat NEB #E7775, New England Biolabs, Ipswich, MA, USA) according to the manufacturer's protocol.

Briefly, mRNA was enriched using oligo(dT) beads. Double-stranded complementary DNA was synthesized, beginning with priming by random hexamers. After terminal repair, polyadenylation, and sequencing adaptor ligation, the cDNA libraries were size-selected and enriched by PCR. The resulting 250-350 bp insert libraries were quantified using a Qubit 2.0 fluorometer (Thermo Fisher Scientific, Waltham, MA, USA) and quantitative PCR. Libraries were sequenced on an Illumina NovaSeq 6000 Platform (Illumina, San Diego, CA, USA) using a paired-end 150 run (2×150 bases). The number of raw reads per sample ranged from 50 to 60 Million. Paired-end reads were aligned to the mouse mm10 build reference genome using the Spliced Transcripts Alignment to a Reference (STAR) software. Identification of differentially abundant transcripts was done using DEseq2. The resulting P values were adjusted using the Benjamini and Hochberg approach for controlling the false discovery rate, and the threshold for differential expression.

Functional Bioinformatics analysis

The list of differentially abundant transcripts (*fro/fro* vs *+fro*) was imported to the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to identify pathway annotations enriched among the proteins encoded by these transcripts. The lists of differentially abundant transcripts (*fro/fro* vs *+fro*) was also imported to the Ingenuity Pathway Analysis (IPA) software (Ingenuity H Systems, www.ingenuity.com) to analyze functional annotations and regulatory networks via upstream regulator analysis, downstream effects analysis, mechanistic networks and causal network analysis. See Supplementary Tables 1 and 2 for up- and down-regulated transcripts.

Exosome isolation and qRT-PCR

Exosomes were isolated from *+fro* and *fro/fro* mice brain as described previously [23,24]. miRNAs were eluted from exosomes using the RNeasy minElute cleanup kit (Qiagen, 74204) and genomic DNA was digested with the RNase-free DNase set (Qiagen, 79254). miRNA reverse transcription was performed using the miRCURY LNA reverse transcription kit (Qiagen, 339340). qRT-PCR was performed to amplify microRNA 223-3p using the primer hsa-miR-223-3p miRCURY LNA miRNA PCR Assay (Qiagen, #339306, gene Globe ID: YP00205986) and LNA SYBR green PCR kit (Qiagen, 339345). Relative-fold changes were normalized comparing exosomal micro-RNA reference gene miR-30c-5p using the primer hsa-miR-30c-5p miRCURY LNA miRNA PCR Assay (Qiagen 339306, gene globe ID YP00204783). Relative fold changes of miR223-3p of *fro/fro* mice were calculated to *+fro* mice by using the formula: Relative value = $2^{-C_t^{\text{geometrical mean of 223p-30c-5p and 30c-5p}}} / 2^{-C_t^{\text{geometrical mean of 30c-5p}}}$. For determination of the amount of exosomes in *+fro* and *fro/fro* mice, the right brain hemispheres of mice were digested in a mixture of papain (Sigma Aldrich, P3125) and hibernate A (Thermo Fisher Scientific, A1247501) at 37 °C for 20 min and centrifuged at 300×g for 5 min. Supernatants were centrifuged at 4000×g for 20 min and the resulting supernatants were recollected for further ultracentrifugation at 10,000×g for 40 min. Finally, exosomes were collected by passing the supernatants through exoEasy columns (Qiagen, 76064) and quantification was performed by nanoparticle tracking analysis (NTA) with ZetaView PMX110 (Particle Metrix).

Statistical Analysis

Statistical analyses and graphing were performed using Microsoft Excel 2019 and GraphPad Prism 8.0 software (GraphPad, San Diego, CA, USA). For IPA analyses, a Z score ($Z < -2.0$ or $Z > 2.0$) was considered significant. When the two groups were compared, student *t* test was used. Values of $P < 0.05$ were considered significant. When multiple groups (>2) were compared, two-way ANOVA was applied.

Results

nSMase2 deficiency prevents age-related increase of ceramide levels in astrocytes

To determine if nSMase2 deficiency affects ceramide levels in the middle-aged brain, the cortex of 10-month old *fro/fro* and *+/fro* (heterozygous littermates) were subjected to targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS). Figure 1 shows that the levels of all ceramide species were decreased in *fro/fro* cortex, with the ceramide species C_{18:0}, C_{18:1}, and C_{24:1} ceramide being downregulated the most. It was previously shown, that these ceramide species were upregulated in the aging brain and serum, and associated with memory impairment, including AD [12,25-30].

Using immunocytochemistry with an anti-ceramide antibody developed in our laboratory [31], we tested if ceramide levels were affected depending on age and cell type. Figure 2 shows that labeling for ceramide was increased up to 4-fold in 10 and 15 month-old *+/fro* mice vs. 3 month-old mice, and in *+/fro* brains (from 15 month-old mice) when compared to 15 month-old *fro/fro* tissue. More importantly, increased ceramide labeling was predominantly colocalized with GFAP positive processes in *+/fro* tissue (arrows), while labeling in neurons was >2 -times lower and confined to perinuclear compartments. In 10 and 15-month-old mice, punctate ceramide labeling was often juxtaposed to astrocytes indicating a secretory process (arrows in Fig. 2B-E). Ceramide labeling of microglia (Iba-1 positive) was not increased during brain aging and it was not altered by nSMase2 deficiency. These data suggest that nSMase2 deficiency mainly prevented elevation of ceramide and its secretion by astrocytes in the middle-aged brain.

nSMase2 deficiency alters mRNA abundance in the middle-aged brain

We performed RNA-seq analyses on *+/fro* and *fro/fro* cortex to screen for clues as to how the lack of ceramide generation due to nSMase2 deficiency affects the middle-aged brain. A total of 1462 transcripts were changed, among them, 891 transcripts were increased and 571 transcripts were decreased. The most increased transcript was *Grin2b* (arrow in Fig. 3A, see also Supplementary Table 1). The differences in transcript abundance observed did not include differences in markers of specific cell types, and therefore did not argue for differences in the proportions of types of neurons or glia between the genotypes tested. Instead, this observation argues that these transcript abundance differences arose from differences in gene expression.

Functional bioinformatics analyses revealed that synaptic signaling annotations were over-represented among the transcripts that were increased in the nSMase2-deficient cortex and many of the encoded proteins, such as *Grin2b*, are important for memory (Fig. 3B

and C, Supplementary Table 1). These analyses also revealed that nSMase2 deficiency was associated with increased levels of mRNAs encoding proteins involved in axonal guidance and long-term potentiation, suggesting that neural plasticity may be enhanced. Furthermore, these analyses revealed that annotations for neurodegenerative conditions such as AD, Parkinson's disease, and Huntington's disease were over-represented among the transcripts that were decreased in *fro/fro* mouse brains (Fig. 3D, Supplementary Table 2). According to the KEGG analysis, also decreased was a set of transcripts encoding mitochondrial complex proteins important for oxidative phosphorylation, indicating that nSMase2 is involved in regulation of mitochondrial oxidative stress (Fig. 3E). These discoveries are consistent with enhanced memory function and increased neural protection, and therefore provide the likely mechanistic explanations for the enhanced memory outcomes observed in *fro/fro* mice [11].

nSMase2 deficiency or inhibition prevents oxidative stress-induced increase of ceramide levels and activation of astrocytes

In astrocytes, oxidative phosphorylation in mitochondria is reduced in favor of aerobic glycolysis, which was suggested to diminish oxidative stress and protect neurons [32-34]. Oxidative stress, however, is increased in reactive astrocytes and induces the production of proinflammatory cytokines [3]. Based on the KEGG pathway enrichment analysis showing that a set of transcripts encoding proteins participating in mitochondrial oxidative phosphorylation were decreased in *fro/fro* brain (Fig. 3D and E), we hypothesized that nSMase2 deficiency decreased oxidative stress-induced astrocyte activation, which was consistent with reduced levels of transcripts for S100 β and C1q, two markers for activated astrocytes (Supplementary Table 2).

Several studies have shown that oxidative stress reduces GSH, which activates nSMase2 and elevates ceramide [14,35-38]. However, these studies did not show intrinsic heterogeneity in the cellular response to stress. Therefore, we used a sensitive imaging method based on fluorescent GSH labeling with monochlorobimane (MCB) and immunolabeling for ceramide and GFAP in primary cultured heterozygous (*+fro*) and *fro/fro* astrocytes exposed to oxidative stress by incubation with tertiary butyl peroxide (tBO2H). Figure 4A shows that incubation of astrocytes with tBO2H led to the reduction of MCB fluorescence in both, *+fro* and *fro/fro* astrocytes, while ceramide labeling was only increased in *+fro* astrocytes. This result indicated that oxidant-induced loss of GSH activated nSMase2 and led to the generation of ceramide in heterozygous astrocytes, which was absent in *fro/fro* astrocytes. Likewise, GFAP labeling, as a marker of activated astrocytes, was only increased in heterozygous cells, indicating that tBO2H incubation led to activation of astrocytes, which required activation of nSMase2 by oxidative stress. This conclusion was further supported by colocalization analyses showing that in control (non-treated) as well as tBO2H-treated heterozygous astrocytes, loss of MCB labeling was associated with strong ceramide labeling, and that the increase of ceramide labeling was directly correlated with that of GFAP (Pearson's colocalization coefficient 0.65 ± 0.15).

To test if restoration of GSH levels prevented oxidative-stress induced activation of nSMase2 and generation of ceramide, we pre-incubated tBO2H-treated wild type astrocytes with N-acetyl cysteine (NACys), an endogenous antioxidant known to provide cysteine to boost

GSH production and reduce oxidative stress *in vitro* and *in vivo* [14,39-41]. Figure 4B shows that NAcCys (NAc) prevented depletion of GSH and increase of ceramide labeling. GW4869, an inhibitor of nSMase2, did not block tBO2H-induced GSH depletion, but prevented the increase of ceramide in the presence of tBO2H, confirming that onset of oxidative stress is upstream of nSMase-2 activation and generation of ceramide. Taken together, these results suggest that oxidative stress leads to the decrease of GSH levels and nSMase2-mediated generation of ceramide in reactive astrocytes.

nSMase2 deficiency reduces astrocyte senescence and inflammation in the brain

Oxidative stress-induced astrocyte activation has been associated with inflammation and astrocyte senescence in the aging brain [3]. Further, the onset of senescence in astrocytes is an essential part of the mechanisms underlying functional decline during brain aging [42]. Since both, oxidative stress and ceramide have been implicated in cellular senescence, we tested if nSMase2 deficiency delayed senescence of astrocytes. We assayed the activity of a senescence marker, β -galactosidase (β -gal), in 2 and 5-weeks old primary cultures of *+/fro* vs. *fro/fro* astrocytes. Figure 5A and B shows that β -gal staining was lower in 2-weeks old than in 5-weeks-old astrocytes. At two weeks in culture, there was no significant difference between nSMase2-deficient (*fro/fro*) and heterozygous (*+/fro*) astrocytes. However, at five weeks in culture, the number of β -gal stained cells was 3-fold lower in *fro/fro* astrocytes when compared to *+/fro* astrocytes, suggesting that nSMase2 deficiency delayed aging and senescence of astrocytes. β -gal staining in aging *+/fro* astrocytes was similar to that in wild type astrocytes, indicating that a single allele of nSMase2 is sufficient for ceramide generation underlying astrocyte senescence (not shown).

Based on the results of the β -gal *in vitro* assay, suggesting that senescence was decreased in nSMase2-deficient astrocytes, we determined the level of senescence markers in *fro/fro* brain tissue. Consistent with the *in vitro* data in primary astrocytes, Figure 5C shows that the levels of two senescence markers, p27 and C3b were lower in the middle-aged *fro/fro* brain as compared to the wild type control and heterozygous mice (Supplementary Fig. 1A). Since senescence in the brain is associated with neuroinflammation, we next determined the level of proinflammatory cytokines using immunoblot analysis. Figure 5D shows that IL-1 β and IL-6, were significantly decreased in *fro/fro* mouse brain, suggesting that nSMase2 deficiency reduces inflammation in the middle-aged brain (see also Supplementary Fig. 1A for original blots and B for comparison of *+/fro* with *fro/fro*).

Upregulation of proinflammatory or senescence markers is characteristic of reactive astrocytes [43]. Proinflammatory cytokines induce tyrosine (Y705) phosphorylation of Stat3, a transcription factor activated in reactive and aging astrocytes [44-47]. Consistent with decreased levels of proinflammatory cytokines, we observed significantly reduced phosphorylation of Stat3 in *fro/fro* brains as compared to wild type (Fig. 5E, see also Supplementary Fig. 1A for original blots and B for comparison of *+/fro* with *fro/fro*). This indicates that nSMase2 participates in the upregulation of inflammation in the middle-aged brain through activation of the Stat3 signaling pathway.

nSMase2 deficiency increases axonal growth and glutamate signaling transcripts

In contrast to the suppressive effect of nSMase2 deficiency on several transcripts encoding proteins important in astrocyte activation, senescence, and neuroinflammation, our data clearly show increases in sets of transcripts encoding proteins involved in axonal guidance/growth and neural signal transmission, especially synaptic signaling and plasticity related to cognition, memory, and learning (Table 3, Supplementary Table 1). Figure 6A displays the primary network identified when the whole set of differentially abundant transcripts was analyzed by IPA. The sub-networks include motor-function related coordination, processing of RNA and several transcription regulation networks, such as those driven by MYC and MYCN. The motor-related behavioral coordination networks involve Grin2b, Grin2a, and BDNF. BDNF is predicted to positively regulate Grin2b in coordination-associated networks (Fig. 6A, B) [48]. More importantly, Grin2b is a critical component of the N-methyl-D-aspartate receptors that mediate forms of long-term potentiation fundamental to cognitive functions and memory (Fig. 7A) [49]. To confirm that upregulation of Grin2b transcript results in increased amount of protein, we determined the protein levels of Grin2b in the brain cortex of both wild type and *fro/fro* mice (10-month-old). Consistent with the RNA-seq data, we found that the protein level of Grin2b in the brain cortex was two-times higher in *fro/fro* mice than in wild type mice (Fig. 7B, Supplementary Table 1, see also Supplementary Fig. 1A for original blots).

Increases in Grin2b mRNA may be induced by nSMase2 deficiency in neurons or other cell types, such as astrocytes. Since immunolabeling for ceramide was increased in astrocytes of the aging brain, we investigated a potential trans-cellular effect of astrocytes on gene expression in neurons. Two potential factors suppressing expression of Grin2b are the neural differentiation transcription factor REST and the micro-RNA miR-223-3p [50,51] (Fig. 8A). We previously published that reactive astrocytes secrete exosomes enriched with ceramide, consistent with punctate labeling for ceramide in juxtaposition to astrocytic processes in 10 and 15-month-old mouse cortex (Fig. 2) [5]. A recent study showed that exosomes secreted by reactive astrocytes were enriched with miR-223-3p and downregulated Grin2b mRNA when added to neuronal cultures [52]. To test if nSMase2 regulated the amount of exosomal miR-223-3p, we performed qRT-PCR for miR-223-3p in brain derived-exosomes from 10-month-old *+fro* and *fro/fro* mice. This experiment did not reveal a significant decrease when compared to exosomal housekeeping micro-RNA (Fig. 8B), but it also did not rule out contributions from small changes in miR-223-3p to the increased amounts of Grin2b in *fro/fro* mice. More importantly, quantitation of exosomes showed that their number was reduced by 70% in the *fro/fro* cortex when compared to that of *+fro* mice (Fig. 8C and D). Therefore, even if the copy number/exosome of miR-223-3p is not significantly reduced, the decrease of exosome secretion due to nSMase2 deficiency will also reduce the number of exosomes carrying miR-223-3p and lower the impact of this micro-RNA on the amount of Grin2b in *fro/fro* mice.

Discussion

We have previously shown that nSMase2 deficiency (*fro/fro* mouse) led to improved cognition in 5XFAD mice [11]. During these studies, we detected marked improvement

of memory function (fear conditioning test) in non-AD *fro/fro* controls when compared to wild type littermates, suggesting that reduced cognitive decline due to nSMase2 deficiency involves mechanisms independent of AD. To identify these mechanisms regulated by nSMase2, we performed transcriptomic (RNA-seq) analyses on cortices of homozygous (*fro/fro*) and heterozygous (*+/fro*) mice. We focused on middle-aged male mice, since our studies on AD showed that cognitive improvement due to nSMase2 deficiency was limited to middle-aged males.

Consistent with improved cognition, RNA-seq analysis revealed increases in clusters of transcripts encoding axonal guidance and synaptic signal transmission proteins in the cortex of *fro/fro* mice (Table 3, Fig. 3, Supplementary Table 1). The coordinated increase in these sets of functionally related transcripts due to nSMase2 deficiency suggests that nSMase2 regulates neuronal function either intrinsically or by trans-cellular effects arising from other cell types, particularly astrocytes. Evidence against effects intrinsic to neurons arises from decreases in transcripts encoding mitochondrial proteins important for oxidative phosphorylation in *fro/fro* cortex (Fig. 3, Supplementary Table 2). Oxidative phosphorylation is critical for neurons, but not for astrocytes, which mainly generate ATP from aerobic glycolysis [32,34]. Hence, if oxidative phosphorylation would be decreased in neurons this would impede enhanced synaptic transmission and cognitive performance, which is contrary to what we observed with *fro/fro* mice [11]. Therefore, we assumed that downregulation of transcripts for oxidative phosphorylation was primarily arising from the effect of nSMase2 deficiency on glial cells. This assumption was supported by recent studies showing that downregulation of oxidative phosphorylation and upregulation of aerobic glycolysis in astrocytes is protective for neurons and ameliorates AD pathology [32,34]. Downregulation of oxidative phosphorylation in astrocytes is also consistent with reduction of glial activation and neuroinflammation as indicated by decreased levels of S100 β and C1q transcripts and proinflammatory cytokines (Figs. 3 and 5D, Supplementary Table 2), as well as reduced astrocyte senescence (Fig. 5A and B). An in-depth analysis of the effect of nSMase2 deficiency on mitochondrial function in astrocytes is beyond the scope of the current study on transcriptomic regulation, but it will be part of follow-up experiments.

Increased astrocyte activation and neuroinflammation are hallmarks of the aging brain and associated with reduced levels of GSH, an endogenous antioxidant mainly produced in astrocytes. There is a strong correlation between cognitive decline and lower levels of GSH [2]. The GSH levels in the brain decrease with age, mainly by being used to neutralize reactive oxygen species (ROS) [53]. Astrocytes are the main source for the GSH precursor dipeptide (Cys-Gly) used for GSH biosynthesis in neurons [16]. Astrocytes maintain their neuroprotective role under acute oxidative stress [54], but they become depleted of GSH during aging and neurodegenerative disease [3]. The immediate target affected by GSH depletion in astrocytes is still unknown. Our *in vitro* experiments with primary cultured astrocytes show that reduction of GSH due to oxidative stress induces generation of ceramide, which is prevented by inhibition or deficiency of nSMase2 (Fig. 4). It is known that the GSH concentration found in astrocytes (5-8 mM) is in the range required for inhibition of nSMase2 [3,10,14-16,55]. Hence, oxidative stress leading to GSH depletion will activate nSMase2 and in turn, induce generation of ceramide.

Lipidomics analysis shows that in the aging brain, all major ceramide species, including those found to be predominantly reduced in nSMase2-deficient *fro/fro* brain ($C_{18:0}$, $C_{18:1}$, and $C_{24:1}$ ceramides) are elevated [25-30]. Since the reduction of GSH levels in the aging brain is strongly associated with cognitive decline, we explored the hypothesis that the decrease of GSH levels leads to the activation of nSMase2 and generation of ceramide. The strongest driver of GSH depletion is oxidative stress leading to reactive oxygen metabolites that deplete GSH. Therefore, it is reasonable to conclude that the *in vitro* experiments showing increased generation of ceramide by oxidative stress-induced activation of nSMase2 in aging astrocytes recapitulate a mechanism similar to that in the aging brain.

Previous studies have shown that oxidative stress activates astrocytes and leads to the secretion of proinflammatory cytokines [43]. Since these cytokines induce activation of nSMase2 and ceramide participates in mediating signaling downstream of cytokine receptors, we tested if neuroinflammation is reduced in nSMase2-deficient brain. The immunoblot data on inflammation and senescence markers showed that *fro/fro* mice cortex contained decreased levels of the proinflammatory cytokines IL-1 β , IL-6, and TNF- α , and lower levels of the senescence markers p27 and C3b (Fig. 5C and D). These data are consistent with a lower phosphorylation level of Stat3 (Y705), the major protein kinase activated by proinflammatory cytokines, upregulated during aging, and characteristic for reactive astrocytes (Fig. 5E) [44-47]. Downregulation of the Stat3-associated cell signaling pathways suggests that activation and senescence of astrocytes are prevented or delayed in nSMase2-deficient *fro/fro* brain. This result is consistent with our *in vitro* data on nSMase2-deficient astrocytes, which age slower than wild type astrocytes as shown by β -galactosidase staining in 2- and 5-week old primary cultures of *fro/fro* vs. *+/fro* astrocytes (Fig. 5A and B).

nSMase2 deficiency is associated with upregulation of sets of transcripts that encode proteins involved in axon development and synaptic signal transmission (Fig. 3). Particularly, the mRNA and protein levels of Grin2b, the b-subunit of the ionotropic glutamate receptor are increased by about 2-fold in *fro/fro* cortex (Figs. 3A and 7B). The level of Grin2b upregulation is similar to that of a transgenic mouse generated about 20 years ago [56,57]. The aged Grin2b overexpressing mice outperformed their wild-type littermates in five different learning and memory behavior tests, including fear conditioning tests. In fact, the performance of these mice in the fear conditioning test was very similar to that of the *fro/fro* mouse, consistent with a similar expression level of Grin2b. Conversely, the subunit composition of the NMDA receptor shows a significant decrease in NR1, NR2A, and NR2B (Grin2b) at the synaptic protein level during aging and in AD [58]. This raises the interesting possibility that downregulation of the NMDA receptor, especially the Grin2b subunit, contributes to decreased cognitive function during the aging process. Therefore, the increased level of Grin2b in *fro/fro* mice suggests that nSMase2 deficiency is beneficial for learning and memory function in the middle-aged brain. It should be noted that our results are different from other studies showing reduced memory function when using younger mice (3-4 months old) with pharmacological inhibition (GW4869) or genetic reduction of nSMase2 activity [59,60]. However, these mice do not represent the age group investigated in our study (10-months old), suggesting that the effect of nSMase2 deficiency on cognition is age-dependent. While at younger age, nSMase2 may contribute to important neuronal

functions, activation of nSMase2 at older age may contribute to impaired cognition by affecting astrocytes.

It has been shown that nSMase2 synthase activity was increased in the aging brain, liver, and kidney [61], which contributes to age-related increases in ceramide levels. Since nSMase2 deficiency decreases the level of ceramide, it is critical to understand how and in which cell type the lack of nSMase2 activity may prevent ceramide-induced effects during aging of the brain and cognitive decline. Since nSMase2 deficiency is not confined to astrocytes, reduction of ceramide levels may be critical in neurons and other cells as well. Immunolabeling for ceramide in cryosections shows that the level of ceramide is mainly increased in astrocytes of the aging brain, and lower in astrocytic processes of *fro/fro* brain (Fig. 2). The absence of ceramide elevation in microglia during aging suggests that it is either not upregulated or converted to other sphingolipids such as sphingosine-1-phosphate, a key regulatory factor in microglia activation [62]. In addition, the punctate labeling of ceramide in close vicinity to GFAP (+) astrocytic processes indicates that ceramide is secreted, which is known for reactive astrocytes that secrete ceramide-enriched exosomes or "astrosomes" [5]. These data suggest that the increase of ceramide in astrocytes of the aging wild type brain may have a trans-cellular effect on other cells such as neurons via secretion of astrosomes.

Recently, it was shown that activated astrocytes secrete exosomes that are enriched with miR-223-3p [52]. This exosomal micro-RNA inhibits inflammation in the peripheral system, while it downregulates Grin2b in neurons (Fig. 8A)[52,63]. Our data show that there is no significant decrease of miR-223-3p when normalized to housekeeping miRNA, however, the total number of exosomes is reduced by 3-fold in *fro/fro* brain, including those carrying miR-223-3p (Fig. 8B-D). These data are consistent with our previous studies showing that nSMase2 deficiency or inhibition reduced exosome secretion from *in vitro*-cultivated astrocytes and brain exosome levels [5,11]. Therefore, it is possible that nSMase2 deficiency reduces the impact of exosomes carrying micro-RNAs that downregulate neuronal function, which could explain the increase of the respective mRNAs levels in *fro/fro* brain.

One may speculate that GSH and ceramide metabolism are intertwined in astrocytes and neurons of the aging brain (Fig. 9). In astrocytes, oxidative phosphorylation is downregulated in favor of aerobic glycolysis, which produces reduction equivalents (NADH) to regenerate GSH. GSH inhibits nSMase2-mediated ceramide generation and secretion of astrosomes. Increased oxidative stress during aging leads to reduction of GSH levels in astrocytes and activation of nSMase2, which induces formation and secretion of aging-associated astrosomes (AAAs) that suppress neuronal activity. In nSMase2-deficient (*fro/fro*) mice, lack of ceramide elevation prevents formation of AAAs, and in turn, preserves neuronal function. Hence, GSH as a sensor for oxidative stress and nSMase2-catalyzed generation of ceramide may constitute a feedback loop for the function of AAAs in the regulation of neuronal activity. There are several exciting questions that remain to be answered about this model. For one, the effect of nSMase2 deficiency on mitochondrial function in astrocytes and its relation to oxidative stress and GSH levels will need to be analyzed *in vivo*. Secondly, the effect of micro-RNAs or lipids in astrosomes on neuronal function will need to be further investigated, particularly with respect to a variety of

micro-RNAs affecting cognition, and lipids such as ceramide or ceramide derivatives (e.g., sphingomyelin, glycosphingolipids) affecting mitochondrial function. Most importantly, we will include a time series in performing lipidomics and transcriptomics analysis comparing mice at different ages. In our future studies, we will further investigate the role of nSMase2 and ceramide in oxidative stress and aging-related regulation of neuronal activity and cognition.

Conclusion

Oxidative stress is associated with brain aging and cognitive decline. The underlying mechanism how oxidative stress impairs brain function is still not clear. We provide evidence that oxidative stress increases ceramide in astrocytes, which is prevented by deficiency of nSMase2, an enzyme that is activated by oxidative stress and generates ceramide from sphingomyelin. Mass spectrometric and transcriptomic (RNA-seq) analyses show that in middle aged (10-month-old) mouse cortex, nSMase2 deficiency reduces ceramide and increases expression of genes important for synaptic transmission, plasticity, and cognition. Therefore, our data show that oxidative stress-induced activation of nSMase2 and generation of ceramide is significant for cognitive decline

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

We thank the Department of Physiology (Chair Dr. Alan Daugherty) at the University of Kentucky, Lexington, KY for institutional support.

Funding

This work was supported in part by NIH grants R01NS095215, R01AG034389, and R01AG064234, and the VA grant I01BX003643 to EB. This work was also supported in part by a BrightFocus grant (A20201464F) to SMC. The lipidomics analysis of this study was supported in part by the Lipidomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313 and P30 GM103339).

List of abbreviations

AAAs	aging-associated astrosomes
Aβ	amyloid beta
AD	Alzheimer's disease
β-gal	β -galactosidase
C1q	Complement factor 1q
Cer	Ceramide
<i>fro/fro</i>	nSMase2-deficient
<i>+/fro</i>	nSMase2 heterozygous

GSH	glutathione
GW	GW4869
IL-1β	interleukin 1 β
IL-6	interleukin 6
IPA	Ingenuity Pathway Analysis
KEGG	Kyoto Encyclopedia of Genes and Genomes
LC-MS/MS	Liquid chromatography-tandem mass spectrometry
MCB	monochlorobimane
NAcCys	N-acetyl cysteine
NR2B/Grin2b	Glutamate Ionotropic Receptor NMDA Type Subunit 2B
nSMase2	neutral sphingomyelinase 2
ROS	Rreactive oxygen species
tBO2H	tertiary butyl hydroperoxide
TNF-α	tumor necrosis factor α
WT	wild type

References

1. Singh-Manoux A, Kivimaki M, Glymour MM, Elbaz A, Berr C, Ebmeier KP, Ferrie JE, Dugravot A (2012) Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. *BMJ* 344:d7622. doi:10.1136/bmj.d7622 [PubMed: 22223828]
2. Hajjar I, Hayek SS, Goldstein FC, Martin G, Jones DP, Quyyumi A (2018) Oxidative stress predicts cognitive decline with aging in healthy adults: an observational study. *J Neuroinflammation* 15 (1):17. doi:10.1186/s12974-017-1026-z [PubMed: 29338747]
3. Lee M, Cho T, Jantaratnotai N, Wang YT, McGeer E, McGeer PL (2010) Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. *FASEB J* 24 (7):2533–2545. doi:10.1096/fj.09-149997 [PubMed: 20228251]
4. de Wit NM, den Hoedt S, Martinez-Martinez P, Rozemuller AJ, Mulder MT, de Vries HE (2019) Astrocytic ceramide as possible indicator of neuroinflammation. *J Neuroinflammation* 16 (1):48. doi:10.1186/s12974-019-1436-1 [PubMed: 30803453]
5. Wang G, Dinkins M, He Q, Zhu G, Poirier C, Campbell A, Mayer-Proschel M, Bieberich E (2012) Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in Alzheimer disease (AD). *J Biol Chem* 287 (25):21384–21395. doi:M112.340513 [pii] 10.1074/jbc.M112.340513 [PubMed: 22532571]
6. Gu L, Huang B, Shen W, Gao L, Ding Z, Wu H, Guo J (2013) Early activation of nSMase2/ceramide pathway in astrocytes is involved in ischemia-associated neuronal damage via inflammation in rat hippocampi. *J Neuroinflammation* 10:109. doi:10.1186/1742-2094-10-109 [PubMed: 24007266]
7. Singh I, Pahan K, Khan M, Singh AK (1998) Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. *J Biol Chem* 273 (32):20354–20362 [PubMed: 9685387]

8. Crivelli SM, Giovagnoni C, Visseren L, Scheithauer AL, de Wit N, den Hoedt S, Losen M, Mulder MT, Walter J, de Vries HE, Bieberich E, Martinez-Martinez P (2020) Sphingolipids in Alzheimer's disease, how can we target them? *Adv Drug Deliv Rev*. doi:10.1016/j.addr.2019.12.003
9. Filippov V, Song MA, Zhang K, Vinters HV, Tung S, Kirsch WM, Yang J, Duerksen-Hughes PJ (2012) Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. *J Alzheimers Dis* 29 (3):537–547. doi:10.3233/JAD-2011-111202 [PubMed: 22258513]
10. Nikolova-Karakashian M, Karakashian A, Rutkute K (2008) Role of neutral sphingomyelinases in aging and inflammation. *Subcell Biochem* 49:469–486. doi:10.1007/978-1-4020-8831-5_18 [PubMed: 18751923]
11. Dinkins MB, Enasko J, Hernandez C, Wang G, Kong J, Helwa I, Liu Y, Terry AV Jr., Bieberich E (2016) Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse. *J Neurosci* 36 (33):8653–8667. doi:10.1523/JNEUROSCI.1429-16.2016 [PubMed: 27535912]
12. Dinkins MB, Dasgupta S, Wang G, Zhu G, He Q, Kong JN, Bieberich E (2015) The 5XFAD Mouse Model of Alzheimer's Disease Exhibits an Age-Dependent Increase in Anti-Ceramide IgG and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden. *J Alzheimers Dis*. doi:46137445150G8266 [pii] 10.3233/JAD-150088
13. Dinkins MB, Dasgupta S, Wang G, Zhu G, Bieberich E (2014) Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease. *Neurobiol Aging* 35 (8):1792–1800. doi:10.1016/j.neurobiolaging.2014.02.012 [PubMed: 24650793]
14. Rutkute K, Asmis RH, Nikolova-Karakashian MN (2007) Regulation of neutral sphingomyelinase-2 by GSH: a new insight to the role of oxidative stress in aging-associated inflammation. *J Lipid Res* 48 (11):2443–2452. doi:10.1194/jlr.M700227-JLR200 [PubMed: 17693623]
15. Liu B, Hannun YA (1997) Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. *J Biol Chem* 272 (26):16281–16287 [PubMed: 9195931]
16. McBean GJ (2017) Cysteine, Glutathione, and Thiol Redox Balance in Astrocytes. *Antioxidants (Basel)* 6 (3). doi:10.3390/antiox6030062
17. Aubin I, Adams CP, Opsahl S, Septier D, Bishop CE, Auge N, Salvayre R, Negre-Salvayre A, Goldberg M, Guenet JL, Poirier C (2005) A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse. *Nat Genet* 37 (8):803–805. doi:ng1603 [pii] 10.1038/ng1603 [PubMed: 16025116]
18. Kong JN, Zhu Z, Itokazu Y, Wang G, Dinkins MB, Zhong L, Lin HP, Elsherbini A, Leanhart S, Jiang X, Qin H, Zhi W, Spassieva SD, Bieberich E (2018) Novel function of ceramide for regulation of mitochondrial ATP release in astrocytes. *J Lipid Res* 59 (3):488–506. doi:10.1194/jlr.M081877 [PubMed: 29321137]
19. Adler J, Parmryd I (2013) Colocalization analysis in fluorescence microscopy. *Methods Mol Biol* 931:97–109. doi:10.1007/978-1-62703-056-4_5 [PubMed: 23026999]
20. Adler J, Parmryd I (2010) Quantifying colocalization by correlation: the Pearson correlation coefficient is superior to the Mander's overlap coefficient. *Cytometry A* 77 (8):733–742. doi:10.1002/cyto.a.20896 [PubMed: 20653013]
21. Bielawski J, Pierce JS, Snider J, Rembiesa B, Szulc ZM, Bielawska A (2009) Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. *Methods Mol Biol* 579:443–467. doi:10.1007/978-1-60761-322-0_22 [PubMed: 19763489]
22. Bielawski J, Pierce JS, Snider J, Rembiesa B, Szulc ZM, Bielawska A (2010) Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). *Adv Exp Med Biol* 688:46–59 [PubMed: 20919645]
23. Elsherbini A, Kirov AS, Dinkins MB, Wang G, Qin H, Zhu Z, Tripathi P, Crivelli SM, Bieberich E (2020) Association of Abeta with ceramide-enriched astrosomes mediates Abeta neurotoxicity. *Acta Neuropathol Commun* 8 (1):60. doi:10.1186/s40478-020-00931-8 [PubMed: 32345374]

24. Elsherbini A, Qin H, Zhu Z, Tripathi P, Crivelli SM, Bieberich E (2020) In vivo evidence of exosome-mediated Aβ neurotoxicity. *Acta Neuropathol Commun* 8 (1):100. doi:10.1186/s40478-020-00981-y [PubMed: 32631455]
25. Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC (2010) Serum sphingomyelins and ceramides are early predictors of memory impairment. *Neurobiol Aging* 31 (1):17–24. doi:10.1016/j.neurobiolaging.2008.03.011 [PubMed: 18455839]
26. Mielke MM, Haughey NJ, Bandaru VV, Schech S, Carrick R, Carlson MC, Mori S, Miller MI, Ceritoglu C, Brown T, Albert M, Lyketsos CG (2010) Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. *Alzheimers Dement* 6 (5):378–385. doi:10.1016/j.jalz.2010.03.014 [PubMed: 20813340]
27. Mielke MM, Lyketsos CG (2010) Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? *Neuromolecular Med* 12 (4):331–340. doi:10.1007/s12017-010-8121-y [PubMed: 20571935]
28. Mielke MM, Bandaru VV, Haughey NJ, Xia J, Fried LP, Yasar S, Albert M, Varma V, Harris G, Schneider EB, Rabins PV, Bandeen-Roche K, Lyketsos CG, Carlson MC (2012) Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. *Neurology* 79 (7):633–641. doi:10.1212/WNL.0b013e318264e380 [PubMed: 22815558]
29. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. *Proc Natl Acad Sci U S A* 101 (7):2070–2075 [PubMed: 14970312]
30. Haughey NJ, Bandaru VV, Bae M, Mattson MP (2010) Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. *Biochim Biophys Acta* 1801 (8):878–886. doi:10.1016/j.bbali.2010.05.003 [PubMed: 20452460]
31. Krishnamurthy K, Dasgupta S, Bieberich E (2007) Development and characterization of a novel anti-ceramide antibody. *J Lipid Res* 48 (4):968–975 [PubMed: 17210985]
32. Demetrius LA, Simon DK (2012) An inverse-Warburg effect and the origin of Alzheimer's disease. *Biogerontology* 13 (6):583–594. doi:10.1007/s10522-012-9403-6 [PubMed: 23086530]
33. Tavallaie M, Voshtani R, Deng X, Qiao Y, Jiang F, Collman JP, Fu L (2020) Moderation of mitochondrial respiration mitigates metabolic syndrome of aging. *Proc Natl Acad Sci U S A* 117 (18):9840–9850. doi:10.1073/pnas.1917948117 [PubMed: 32303655]
34. Zheng J, Xie Y, Ren L, Qi L, Wu L, Pan X, Zhou J, Chen Z, Liu L (2021) GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease. *Mol Metab*:101180. doi:10.1016/j.molmet.2021.101180 [PubMed: 33556642]
35. Yoshimura S, Banno Y, Nakashima S, Hayashi K, Yamakawa H, Sawada M, Sakai N, Nozawa Y (1999) Inhibition of neutral sphingomyelinase activation and ceramide formation by glutathione in hypoxic PC12 cell death. *J Neurochem* 73 (2):675–683. doi:10.1046/j.1471-4159.1999.0730675.x [PubMed: 10428064]
36. Denisova NA, Cantuti-Castelvetri I, Hassan WN, Paulson KE, Joseph JA (2001) Role of membrane lipids in regulation of vulnerability to oxidative stress in PC12 cells: implication for aging. *Free Radic Biol Med* 30 (6):671–678. doi:10.1016/s0891-5849(00)00513-x [PubMed: 11295365]
37. Sofic E, Denisova N, Youdim K, Vatrejak-Velagic V, De Filippo C, Mehmedagic A, Causevic A, Cao G, Joseph JA, Prior RL (2001) Antioxidant and pro-oxidant capacity of catecholamines and related compounds. Effects of hydrogen peroxide on glutathione and sphingomyelinase activity in pheochromocytoma PC12 cells: potential relevance to age-related diseases. *J Neural Transm (Vienna)* 108 (5):541–557. doi:10.1007/s007020170055 [PubMed: 11459075]
38. Ichi I, Kamikawa C, Nakagawa T, Kobayashi K, Kataoka R, Nagata E, Kitamura Y, Nakazaki C, Matsura T, Kojo S (2009) Neutral sphingomyelinase-induced ceramide accumulation by oxidative stress during carbon tetrachloride intoxication. *Toxicology* 261 (1-2):33–40. doi:10.1016/j.tox.2009.04.040 [PubMed: 19394401]
39. Skvarc DR, Dean OM, Byrne LK, Gray L, Lane S, Lewis M, Fernandes BS, Berk M, Marriott A (2017) The effect of N-acetylcysteine (NAC) on human cognition - A systematic review. *Neurosci Biobehav Rev* 78:44–56. doi:10.1016/j.neubiorev.2017.04.013 [PubMed: 28438466]

40. Cao L, Li L, Zuo Z (2012) N-acetylcysteine reverses existing cognitive impairment and increased oxidative stress in glutamate transporter type 3 deficient mice. *Neuroscience* 220:85–89. doi:10.1016/j.neuroscience.2012.06.044 [PubMed: 22732503]
41. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, Morley JE (2003) The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. *J Neurochem* 84 (5):1173–1183 [PubMed: 12603840]
42. Cohen J, Torres C (2019) Astrocyte senescence: Evidence and significance. *Aging Cell* 18 (3):e12937. doi:10.1111/ace1.12937 [PubMed: 30815970]
43. Escartin C, Galea E, Lakatos A, O'Callaghan JP, Petzold GC, Serrano-Pozo A, Steinhauser C, Volterra A, Carmignoto G, Agarwal A, Allen NJ, Araque A, Barbeito L, Barzilai A, Bergles DE, Bonvento G, Butt AM, Chen WT, Cohen-Salmon M, Cunningham C, Deneen B, De Strooper B, Diaz-Castro B, Farina C, Freeman M, Gallo V, Goldman JE, Goldman SA, Gotz M, Gutierrez A, Haydon PG, Heiland DH, Hol EM, Holt MG, Iino M, Kastanenka KV, Kettenmann H, Khakh BS, Koizumi S, Lee CJ, Liddelow SA, MacVicar BA, Magistretti P, Messing A, Mishra A, Molofsky AV, Murai KK, Norris CM, Okada S, Oliet SHR, Oliveira JF, Panatier A, Parpura V, Pekna M, Pekny M, Pellerin L, Perea G, Perez-Nievas BG, Pfrieger FW, Poskanzer KE, Quintana FJ, Ransohoff RM, Riquelme-Perez M, Robel S, Rose CR, Rothstein JD, Rouach N, Rowitch DH, Semyanov A, Sirko S, Sontheimer H, Swanson RA, Vitorica J, Wanner IB, Wood LB, Wu J, Zheng B, Zimmer ER, Zorec R, Sofroniew MV, Verkhratsky A (2021) Reactive astrocyte nomenclature, definitions, and future directions. *Nat Neurosci* 24 (3):312–325. doi:10.1038/s41593-020-00783-4 [PubMed: 33589835]
44. O'Callaghan JP, Kelly KA, VanGilder RL, Sofroniew MV, Miller DB (2014) Early activation of STAT3 regulates reactive astrogliosis induced by diverse forms of neurotoxicity. *PLoS One* 9 (7):e102003. doi:10.1371/journal.pone.0102003 [PubMed: 25025494]
45. Hashioka S, Klegeris A, Qing H, McGeer PL (2011) STAT3 inhibitors attenuate interferon-gamma-induced neurotoxicity and inflammatory molecule production by human astrocytes. *Neurobiol Dis* 41 (2):299–307. doi:10.1016/j.nbd.2010.09.018 [PubMed: 20888416]
46. Herrmann JE, Imura T, Song B, Qi J, Ao Y, Nguyen TK, Korsak RA, Takeda K, Akira S, Sofroniew MV (2008) STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. *J Neurosci* 28 (28):7231–7243. doi:10.1523/JNEUROSCI.1709-08.2008 [PubMed: 18614693]
47. White CW 3rd, Fan X, Maynard JC, Wheatley EG, Bieri G, Couthouis J, Burlingame AL, Villeda SA (2020) Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation. *Proc Natl Acad Sci U S A* 117 (36):22214–22224. doi:10.1073/pnas.2007439117 [PubMed: 32848054]
48. Zhang Y, Ji F, Wang G, He D, Yang L, Zhang M (2018) BDNF Activates mTOR to Upregulate NR2B Expression in the Rostral Anterior Cingulate Cortex Required for Inflammatory Pain-Related Aversion in Rats. *Neurochem Res* 43 (3):681–691. doi:10.1007/s11064-018-2470-6 [PubMed: 29353374]
49. Gozlan H, Khazipov R, Ben-Ari Y (1995) Multiple forms of long-term potentiation and multiple regulatory sites of N-methyl-D-aspartate receptors: role of the redox site. *J Neurobiol* 26 (3):360–369. doi:10.1002/neu.480260308 [PubMed: 7775969]
50. Rodenas-Ruano A, Chavez AE, Cossio MJ, Castillo PE, Zukin RS (2012) REST-dependent epigenetic remodeling promotes the developmental switch in synaptic NMDA receptors. *Nat Neurosci* 15 (10):1382–1390. doi:10.1038/nn.3214 [PubMed: 22960932]
51. Harraz MM, Eacker SM, Wang X, Dawson TM, Dawson VL (2012) MicroRNA-223 is neuroprotective by targeting glutamate receptors. *Proc Natl Acad Sci U S A* 109 (46):18962–18967. doi:10.1073/pnas.1121288109 [PubMed: 23112146]
52. Amoah SK, Rodriguez BA, Logothetis CN, Chander P, Sellgren CM, Weick JP, Sheridan SD, Jantzie LL, Webster MJ, Mellios N (2020) Exosomal secretion of a psychosis-altered miRNA that regulates glutamate receptor expression is affected by antipsychotics. *Neuropsychopharmacology* 45 (4):656–665. doi:10.1038/s41386-019-0579-1 [PubMed: 31775160]
53. Zhu Y, Carvey PM, Ling Z (2006) Age-related changes in glutathione and glutathione-related enzymes in rat brain. *Brain Res* 1090 (1):35–44. doi:10.1016/j.brainres.2006.03.063 [PubMed: 16647047]

54. Bhatia TN, Pant DB, Eckhoff EA, Gongaware RN, Do T, Hutchison DF, Gleixner AM, Leak RK (2019) Astrocytes Do Not Forfeit Their Neuroprotective Roles After Surviving Intense Oxidative Stress. *Front Mol Neurosci* 12:87. doi:10.3389/fnmol.2019.00087 [PubMed: 31024254]
55. Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA (1998) Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. *J Biol Chem* 273 (18):11313–11320 [PubMed: 9556624]
56. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ (1999) Genetic enhancement of learning and memory in mice. *Nature* 401 (6748):63–69. doi:10.1038/43432 [PubMed: 10485705]
57. Cao X, Cui Z, Feng R, Tang YP, Qin Z, Mei B, Tsien JZ (2007) Maintenance of superior learning and memory function in NR2B transgenic mice during ageing. *Eur J Neurosci* 25 (6):1815–1822. doi:10.1111/j.1460-9568.2007.05431.x [PubMed: 17432968]
58. Avila J, Llorens-Martin M, Pallas-Bazarrá N, Bolos M, Perea JR, Rodríguez-Matellán A, Hernández F (2017) Cognitive Decline in Neuronal Aging and Alzheimer's Disease: Role of NMDA Receptors and Associated Proteins. *Front Neurosci* 11:626. doi:10.3389/fnins.2017.00626 [PubMed: 29176942]
59. Kalinichenko LS, Abdel-Hafiz L, Wang AL, Muhle C, Rosel N, Schumacher F, Kleuser B, Smaga I, Frankowska M, Filip M, Schaller G, Richter-Schmidinger T, Lenz B, Gulbins E, Kornhuber J, Oliveira AWC, Barros M, Huston JP, Muller CP (2021) Neutral Sphingomyelinase is an Affective Valence-Dependent Regulator of Learning and Memory. *Cereb Cortex* 31 (2):1316–1333. doi:10.1093/cercor/bhaa298 [PubMed: 33043975]
60. Tabatadze N, Savonenko A, Song H, Bandaru VV, Chu M, Haughey NJ (2010) Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice. *J Neurosci Res* 88 (13):2940–2951. doi:10.1002/jnr.22438 [PubMed: 20629193]
61. Sackett SJ, Chung HY, Okajima F, Im DS (2009) Increase in sphingolipid catabolic enzyme activity during aging. *Acta Pharmacol Sin* 30 (10):1454–1461. doi:10.1038/aps.2009.136 [PubMed: 19749786]
62. Zhong L, Jiang X, Zhu Z, Qin H, Dinkins MB, Kong JN, Leanhart S, Wang R, Elsherbini A, Bieberich E, Zhao Y, Wang G (2019) Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to amyloid-beta peptide. *Glia* 67 (3):498–511. doi:10.1002/glia.23558 [PubMed: 30484906]
63. Lu FB, Chen DZ, Chen L, Hu ED, Wu JL, Li H, Gong YW, Lin Z, Wang XD, Li J, Jin XY, Xu LM, Chen YP (2019) Attenuation of Experimental Autoimmune Hepatitis in Mice with Bone Mesenchymal Stem Cell-Derived Exosomes Carrying MicroRNA-223-3p. *Mol Cells* 42 (12):906–918. doi:10.14348/molcells.2019.2283 [PubMed: 31826604]




Figure 1. Spingolipidomics (LC-MS/MS) analysis shows that the levels of all ceramide species are reduced in the nSMase2-deficient cortex (*fro/fro*, red) compared to heterozygous controls (*+/fro*, blue). In the truncated violin plot, black dots in white lines indicate the median value. Ceramide concentrations were normalized to lipid phosphate. N=3, 10-month-old male. Student *t*-test. ** $P < 0.01$ and * $P < 0.05$ for the difference in the levels of C18:0, C18:1, C20:1, and C20 ceramide.




Figure 2. Ceramide is mainly increased in astrocytes during aging of the brain

(A-E) Immunocytochemistry shows that ceramide labeling (red) mainly increases in 10 and 15-month old (B-D, arrows) vs. 3-month old heterozygous (+/fro) cortex (A). Ceramide labeling is localized in astrocytes (GFAP, green) and to a lesser extent in microglia (purple in C) and neurons (purple in D). Punctate labeling of ceramide is also visible in close vicinity to astrocytic processes (arrows in B and E) and it is reduced in 15-month old *fro/fro* mice (E). (F) Quantitation of colocalization using Pearson's coefficient for colabeling of ceramide with markers for astrocytes, (GFAP), microglia (Iba1), and neurons (Neurotrace). N=8. Unpaired *t*-test and ANOVA. *P*-values are given in figure.




Figure 3. nSMase2-sensitive transcripts are related to oxidative phosphorylation, ribosome biogenesis, synaptic transmission, plasticity, and memory
 (A) Volcano plot shows differentially abundant transcripts in homozygous (*fro/fro*) vs. heterozygous (*+/fro*) mouse cortex. Red labels denote increased and green decreased transcripts in *fro/fro* cortex. The two transcripts decreased most are cytochrome c oxidase subunit VIIa polypeptide 2-like pseudogene (Gm6969) (and ribosomal protein L30 (RPL30). The transcript most increased is Grin2b (NMDA receptor subunit 2B, arrow). (B) IPA analysis shows that Grin2b is one of a set transcripts encoding proteins important for memory that are increased in *fro/fro* mice. (C, D) KEGG pathway enrichment analysis of over-represented functional relationships among transcripts increased in *fro/fro* (CThom) cortex as compared to *+/fro* (CThet) cortex, showing the top 10 most significant biological pathways. (E) KEGG pathway analysis of oxidative phosphorylation shows the protein assembly in oxidative phosphorylation depicting five mitochondrial complexes containing proteins encoded by transcripts decreased in *fro/fro* mice. The color legend represents *fro/fro*

vs. \pm *fro* \log_2 FC with red denoting upregulation, green denoting downregulation, and grey indicating \log_2 FC is zero.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Oxidative stress reduces GSH levels and increases nSMase2-mediated ceramide generation in reactive astrocytes

(A) Oxidative stress induced by treatment of heterozygous (*+/fro*) astrocytes for 1 h with 200 μ M tBO2H led to the depletion of GSH (MCB labeling) and increase of ceramide and GFAP labeling, while nSMase2-deficient (*fro/fro*) astrocytes showed no increase of ceramide or GFAP levels. There is no colabeling of GSH with ceramide. (B) Inhibition of nSMase2 with GW4869 (10 μ M) or restoration of GSH with NAcCys (500 μ M) prevents ceramide generation induced by oxidative stress (100 μ M tBO2H for 2 h).




Figure 5. nSMase2 regulates expression of senescence markers, pro-inflammatory cytokines and Stat3 activation

(A, B) β -galactosidase staining in two and five-weeks old cultures of primary *+/fro* and *fro/fro* astrocytes. Five-weeks old cultures of primary *fro/fro* astrocytes show significantly less staining than heterozygous (*+/fro*) astrocytes. N=3. (C-E) Immunoblots for senescence markers p27 and C3b (C), cytokines (IL-1 β , IL-6, and TNF- α) (D), and pStat3 and Stat3 (E) in protein prepared from 10-months old male wild type (WT) and nSMase2-deficient (*fro/fro*) cortex. N=3. Unpaired *t*-test. $P < 0.01$.




Figure 6. nSMase2 regulates Grin2b transcription networks
 (A) IPA analysis of the set of differentially abundant transcripts shows the most enriched mechanistic network, including motor behavioral coordination-associated networks and processing of RNA. The legends of network and path designer shapes have been listed underneath of networks, red color denotes activated function and blue color denotes inhibited function. (B) Grin2b, Grin2a, and BDNF were predicted to be coordinately upregulated in *fro/fro* cortex.




Figure 7. nSMase2 deficiency increases Grin2b expression
 (A) Synaptic network for receptor cell signaling upregulated in *fro/fro* cortex, including NMDA receptor (circled in red) containing Grin2a and Grin2b subunits. (B) Protein analysis of Grin2b in *fro/fro* cortex as compared to wild type controls. N=3 pairs (littermates from 3 dams), two tails paired *t*-test. *P* < 0.05.




Figure 8. nSMase2 deficiency reduces the number of exosomes that decrease Grin2b (A) The upstream regulator analysis by IPA showing transcripts downstream of REST and miR-223-3p that is decreased in *fro/fro* cortex. Inhibition of REST and miR-223-3p (blue) activate Grin2b. The transcripts downstream of REST and miR-223-3p are positively associated with neuron number, long-term potentiation, epilepsy, behavioral conditioning, and memory. (B) qPCR for miR-223-3p in exosomes from *fro/fro* and *+/fro* brain. Plot shows fold-change when compared to exosomal house keeping miRNA (miR-30c-5p). N=3, unpaired *t*-test. (C, D) Nanoparticle tracking analysis (Zetaview) of extracellular vesicles from *+/fro* and *fro/fro* cortex. The number of exosomes are shown as per milliter (ml) of PBS or per gram (gm) of brain tissues N=3. Unpaired *t*-test. $P < 0.01$ (C) and 0.05 (D).




Figure 9. Hypothetical model for regulation of neuronal function by nSMase2 in astrocytes and aging-associated astrosomes (AAAs)

Oxidative stress leads to the generation of reactive oxygen species (ROS) in astrocytes and in neurons. In astrocytes, GSH is secreted to provide GSH precursors to neurons. In neurons, GSH resynthesized from astrocytes-derived precursors neutralizes ROS to maintain neuronal function. Increased oxidative stress during aging leads to reduction of GSH levels in astrocytes and activation of nSMase2, which induces formation and secretion of aging-associated astrosomes (AAAs) that suppress neuronal activity, probably through ceramide and micro-RNAs. In nSMase2-deficient (*fro/fro*) mice, lack of ceramide elevation prevents formation of AAAs, and in turn, preserves neuronal function.

Table 1.

List of Antibodies used in the study

Antibodies	Ratio	Cat#	Company
Anti-IL-1 β	1:250	SC-32294	Santa Cruz
Anti-IL-6	1:250	SC-32296	Santa Cruz
Anti-TNF α	1:250	SC-12744	Santa Cruz
Anti-NR2B	1:1000	06-600	Millipore Sigma
Anti-Stat3	1:1000	#4904	Cell Signaling
Anti-pStat3	1:1000	#9145	Cell Signaling
Anti-P27 kip1	1:1000	#2552	Cell Signaling
Anti-ceramide rabbit IgG	1:100	Were generated in our laboratory	
Anti-ceramide mouse IgM	1:100	MAS0014	Glycobiotech
Anti-rabbit HRP	1:5000	715-035-152	Jackson Immune Research
Anti-mouse HRP	1:5000	715-035-151	Jackson Immune Research
Anti-GAPDH	1:5000	#5174	Cell signaling tech
Anti-GFAP	1:10,000	20071831	DaKo
Anti-C3b	1:1000	21337-1-AP	Protein Tech

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

Chemicals and Kits used in the study

Reagents	Cat#	Company
SDS-PAGE sample buffer	S3401-1VL	Sigma-Aldrich
Protease and phosphatase inhibitors	A32961	ThermoFisher Scientific
Fetal Bovine Serum	E19057	Atlanta Biologicals
DMEM	2261905	Hyclon
Penicillin and streptomycin	15146	GIBCO
GW4869	6823-69-4	Cayman
tBO2H	458139	Sigma-Aldrich
N-acetyl-L-Cysteine (NACys)	20261	Cayman
β -galactosidase	#9860	Cell signaling tech
Monochlorobimane (MCB)	69899	Sigma-Aldrich
RNeasy plus mini kit	74134	QIAGEN
RNeasy minElute cleanup kit	74204	QIAGEN
RNase-Free DNase set	79254	QIAGEN
miRCURY LNA reverse transcription kit	339340	QIAGEN
primer hsa-miR-223-3p miRCURY LNA miRNA PCR Assay	339306	QIAGEN
LNA SYBR green PCR kit	339345	QIAGEN
exoEasy column	76064	QIAGEN
Hibernate A	A1247501	Thermo Fisher Scientific
papain	P3125	Sigma Aldrich

Table 3.
Behavior-related functional analysis of transcripts

Transcripts analyzed by IPA software showing the annotation of neuronal functions are predicted to be significantly upregulated (Z score >2.0). The upregulated functions include cognition, learning, conditioning and memory. The number of molecules (# Molecules), which contribute to the activation of functions are also provided for each category of functional annotation.

Function Annotation	p -value	Predicted activation state	Activation z-score	#Molecules
Cognition	4.04E-23	Increased	2.995	118
Learning	1.76E-20	Increased	3.008	106
Conditioning	2.47E-09	Increased	2.976	46
Memory	1.26E-12	Increased	3.591	64